U.S. Trade Representative Katherine Tai announced May 5 that the U.S. will support an intellectual property waiver for COVID-19 vaccines, but she cautioned that negotiating the language in Geneva will take time, because of both the need for consensus at the World Trade Organization and the “complexity of the issues.” Top Democrats in Congress welcomed the announcement. Tai also said the administration will work to increase production of raw materials for vaccines.
U.S. Trade Representative Katherine Tai will testify on the administration's trade policy agenda next week, appearing May 12 at 9:30 a.m. before the Senate Finance Committee and May 13 at 10 a.m. before the House Ways and Means Committee.
Export Compliance Daily is providing readers with the top stories for April 26-30 in case you missed them. You can find any article by searching on the title or by clicking on the hyperlinked reference number.
U.S. Trade Representative Katherine Tai announced May 5 that the U.S. will support an intellectual property waiver for COVID-19 vaccines, but cautioned that negotiating the language in Geneva will take time, because of the need for consensus at the World Trade Organization, and because of the “complexity of the issues.” Top Democrats in Congress welcomed the announcement. Tai also said the administration will work to increase production of raw materials for vaccines, which has been the constraint so far for Indian vaccine manufacturers. Pfizer has expressed interest in manufacturing in India if it would speed approval of its vaccine; India currently does not allow imports of Johnson & Johnson, Pfizer or Moderna vaccines.
Member nations of the World Trade Organization agreed to continue consideration of the temporary waiver on certain intellectual property requirements for COVID-19 vaccine production, at an April 30 meeting of the Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS), the WTO announced in a press release. The waiver proposal was submitted by South Africa and India but faces opposition from some of the globe's wealthiest countries, such as the U.S., the United Kingdom and countries in the European Union, that have blocked the plan. The chair of the council is tasked with reporting to the General Council on the group's decision regarding the IP waiver at the next meeting on May 5-6.
With the administration's desire to address root causes for migration from Central American countries, U.S. Trade Representative Katherine Tai said the free trade agreement that covers that region, and the Dominican Republic, has been “very much on my mind recently.”
In an annual report about intellectual property challenges around the globe, the Office of the U.S. Trade Representative praised progress at the United Arab Emirates, and repeated concerns about dozens of countries' weak enforcement and policies it says are barriers to U.S. businesses. China, India, Russia, Argentina, Chile, Indonesia, Saudi Arabia, Ukraine and Venezuela spent another year on the USTR's "priority watch list" for intellectual property violations, while Algeria moved to the lower-intensity "watch list."
U.S. Trade Representative Katherine Tai heard many bipartisan complaints about the pain of both Section 301 tariffs and Europe's retaliatory tariffs in response to steel tariffs, but stood her ground on both during a hearing in front of a Senate Appropriations subcommittee responsible for funding the Office of the U.S. Trade Representative.
U.S. Trade Representative Katherine Tai published a readout of video calls she had with the leader of AstraZeneca's U.S. business and Pfizer's CEO on whether there should be a waiver of the World Trade Organization's agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). The readouts did not say what either the government or companies' positions are on a TRIPS waiver, and during a background call on aid to India to combat its surge of cases and deaths, an official also sidestepped a question on the waiver. The readouts said that Tai “emphasized her commitment to working with WTO members on a global pandemic response, including the role of developing countries in any effective solution that addresses critical gaps in global production and distribution of vaccines”; and that the Pfizer CEO also wants to improve global access to the vaccine, and he discussed “how trade policy could help address the challenges of increasing vaccine production and distribution around the world.”
At a webinar on U.S.-Vietnam economic relations, Ambassador Ha Kim Ngoc said Vietnam is working to narrow the trade deficit with the U.S., whether by buying more American agricultural exports or encouraging Vietnamese businesses to open factories in the U.S. "I don’t think we can solve the problem overnight, with COVID-19 and the increased demand of the goods from Southeast Asia, and particularly Vietnam," he said April 27.